[Candidiasis].
Diabetes mellitus (DM) has been considered to predispose to candidiasis. While poor glycemic control increases the risk of superficial candidiasis (especially oral candidiasis), invasive candidiasis is not related to DM. Invasive candidiasis is diagnosed by combination of clinical manifestation, laboratory findings and isolation of Candida spp. Strategy of treatment for invasive candidiasis is consist of prophylactic, empiric and targeted therapy. MCFG, FLCZ and AMPH-B are recommended as first line drugs for invasive candidiasis, and L-AMB, VRCZ, ITCZ are considered as alternative drugs in Japanese guideline.
Imamura
Yoshifumi
Y
Second Department of Internal Medicine, Nagasaki University School of Medicine.
Izumikawa
Koichi
K
Kohno
Shigeru
S
D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage; D000946:Antigens, Fungal / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002175:Candida / Q000276:immunology / Q000302:isolation & purification; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D048909:Diabetes Complications; D054714:Echinocandins / Q000008:administration & dosage; D015725:Fluconazole / Q000008:administration & dosage; D006801:Humans; D055666:Lipopeptides / Q000008:administration & dosage; D000077551:Micafungin; D011509:Proteoglycans; D047071:beta-Glucans / Q000097:blood
D000935:Antifungal Agents; D000946:Antigens, Fungal; D015415:Biomarkers; D054714:Echinocandins; D055666:Lipopeptides; D011509:Proteoglycans; D047071:beta-Glucans; C010770:polysaccharide-K; D000666:Amphotericin B; D015725:Fluconazole; D000077551:Micafungin